Autor: websites

Industry expert, Dr. Jafar Jafari, teases new book, The Essential Guide to Hydrogen and Methane Breath Testing, at UEG Week 2023

Posted on

Dr Jafar Jafari, Head of Upper GI Physiology Service at Guy’s and St Thomas‘, announces new book in the works highlighting the benefits of HMBT

Dr. Jafar Jafari, expert in the field of gastroenterology, is excited to announce the forthcoming release of his groundbreaking book, „The Essential Guide to Hydrogen and Methane Breath Testing.“ at one of the largest Gastroenterology congresses in the world, UEG Week 2023.

Gastrointestinal disorders affect millions of individuals globally, impacting their quality of life and often leading to substantial healthcare costs. Dr Jafari’s new book offers “A Modern Approach to Investigating Gastrointestinal Disorders”, shining a light on the transformative potential of Hydrogen Methane Breath testing (HMBT) to aid in the diagnosis and treatment of various gastrointestinal conditions.

In this comprehensive and expertly researched book, Dr. Jafari delves deep into the science behind HMBT, exploring its role in reshaping the way we understand and manage gastrointestinal health. This book will be published in 2024, and will be published in partnership with leading medical device manufacturer, Bedfont® Scientific Ltd.

Jason Smith, Managing Director at Bedfont®, comments, „We are excited to be working with Dr Jafari on the upcoming release of his new book, we believe it will really help healthcare professionals to unlock the potential of HMBT in Gastroenterology.”

Dr. Jafari, explains, “I have the opportunity to share my knowledge and passion for gastrointestinal health with the next generation of healthcare professionals. This book is a culmination of my experiences, insights, and dedication to the field. I hope it serves as a valuable practical resource for those seeking a deeper understanding of hydrogen and methane breath testing, ultimately leading to improved patient care and outcomes.”

While the official book launch is scheduled for 2024, attendees of UEG 2023 will have the opportunity to get a sneak peek at the book’s content and meet the author, Dr. Jafar Jafari. They can also engage in discussions about the book’s content, its implications for the field, and the future of gastroenterology. This year, UEG 2023 takes place on October 14 – 17, at the Bella Center in Copenhagen; Dr. Jafari will be at Bedfont’s stand, C3-70.

Carol Stonham MBE, RN, MSc, Queen’s Nurse, and Policy Lead PCRS joins the Bedfont® Medical Advisory Board

Posted on

Esteemed Respiratory Healthcare Expert, Carol Stonham, Joins the Medical Advisory Board for Medtech Company, Bedfont Scientific Ltd.

Bedfont® Scientific Ltd, a leading innovator in breath analysis medical device technology, is proud to announce the addition of Carol Stonham, a highly respected and accredited respiratory healthcare expert, to its esteemed medical board. This appointment further strengthens Bedfont’s commitment to revolutionising respiratory healthcare solutions and delivering cutting-edge products to patients and healthcare professionals.

Carol brings an extensive background in respiratory healthcare and in particular Asthma and FeNO (Fractional Exhaled Nitric Oxide). She has worked in primary care in Gloucestershire for over 26 years. Her role includes running a local FeNO referral service whilst being a CCG Primary Care Nurse Practitioner for Respiratory Care. Her experience extends even further in this clinical field as she is an active member of the PCRS and currently Policy Lead.

Jason Smith, Managing Director at Bedfont®, exclaims, „We are thrilled to welcome Carol to our Medical Advisory Board. Her expertise and dedication to improving respiratory healthcare align perfectly with our vision to foster a world where everyone has access to instant, non-invasive, simple breath testing to aid in medical diagnosis. As Helen Keller said, ‘Alone we can do so little; together we can do so much’. With Carol’s fantastic knowledge and passion for FeNO, we hope to work together to improve asthma management and diagnosis worldwide.”

Carol, adds, „I am delighted to be part of the Bedfont Medical Advisory Board and to collaborate in the advancement of respiratory healthcare. I look forward to working with Bedfont and fellow board members and leveraging my experience to drive innovation in this critical field. I have been passionate about FeNO for a number of years now and my main interest is improving the industry standards and the care we deliver to our patients.“

Bedfont’s mission is to work with the Bedfont Family and healthcare professionals worldwide to provide cutting-edge breath analysis medical products to the highest standard, through technical innovation and professional business practice. The addition of Carol Stonham to its medical board underscores its dedication to delivering excellence in respiratory healthcare.

To learn more about Carol, watch her introduction here: https://www.youtube.com/watch?v=Z_15x3eanM8

Prioritising Lung Health: How FeNO can help to tackle Lung Conditions, the UK’s 3rd Largest Threat

Posted on

Harnessing the Power of FeNO Monitoring to Combat Lung Conditions – A Vital Step in Addressing the UK’s Lung Health Crisis

A new report from PwC commissioned by Asthma+Lung UK has highlighted the alarming crisis surrounding Lung Health in the UK. Sarah Woolnough, CEO of Asthma+Lung UK, said lung conditions were the third biggest killer in the UK, with the report finding that due to the lack of testing, such as FeNO monitoring, patients can also be wrongly diagnosed and an estimated 750,000 people in England are misdiagnosed with asthma, costing the NHS an estimated £132 million every year1.

Fractional Exhaled Nitric Oxide (FeNO) is a non-invasive medical test that measures the level of nitric oxide in a person’s breath. It is a pivotal advancement in asthma care, offering precise insights into airway inflammation. By facilitating accurate diagnoses, personalising treatment plans, and enabling ongoing monitoring of asthma control, FeNO empowers healthcare providers to optimise medication use, reduce exacerbations, and enhance patient engagement. This transformative tool not only improves the quality of life for individuals with asthma but also contributes to more effective, cost-efficient healthcare management, ultimately making a profound impact on the battle against this chronic respiratory condition.

Carol Stonham MBE, RN, MSc, Queen’s Nurse, and Policy Lead PCRS, explains, “Making an accuratediagnosis of asthma relies on taking an accurate history and then performing appropriate tests to confirm the diagnosis. Spirometry (a test of lung function) was stopped during the pandemic and hasbeen very slow to restart. FeNO testing provides a valuable piece of the jigsaw to confirm whether a person has asthma (or not). It is a very quick test to perform and most people find it easy to do. The basis of asthma is airway inflammation which is what the FeNO test gives an indication of. It helps confirm a diagnosis quickly and easily and helps the patient better understand their condition and how inhalers work to treat the condition. It helps clinicians make the correct diagnosis in a timely way and get the person onto the correct treatment pathway avoiding unnecessary hospital admission and life-threatening asthma attacks.”

Jason Smith, Managing Director at Bedfont Scientific, comments, “As a leading manufacturer of breath analysis medical devices, we understand the pivotal role that innovation plays in enhancing patient care and healthcare efficiency. FeNO testing is a prime example of such innovation. We remain committed to advancing respiratory care and hope that in working towards our mission to make healthcare more accessible, our NObreath® FeNO monitor can help make a positive impact on the lives of individuals living with asthma.“

Livio Gagliardi, Acting Managing Director at Intermedical, adds, “As the official UK distributor for NObreath®, we understand the significance of accessibility and affordability. We take pride in offering a flexible three-year rental plan for the NObreath® FeNO device. Our aim is to support practices and Primary Care Networks, regardless of their size or testing volume, in ensuring equal access to FeNO testing for their patients. We are well aware of the financial constraints faced by healthcare providers and patients alike.”“What sets us apart is our democratic cost per test pricing policy. We do not penalise smaller practices; instead, we maintain a low fixed cost per test, regardless of the volume of tests conductedper year. This means that even the smallest practices can benefit from our cost-effective solution. Our rental program for the NObreath® FeNO device serves as a crucial link, as we actively strive to narrow the gap and make advanced respiratory care accessible to everyone.”

The full report can be found here: https://www.asthmaandlung.org.uk/saving-your-breath

To contact Intermedical, please call 01732 522444 or email sales@intermedical.co.uk

References

  1. Asthma+Lung UK. Saving Your Breath: How Better Lung Health Benefits Us All. September 2023. Available from: https://www.asthmaandlung.org.uk/saving-your-breath-report

World Lung Day – 25th September 2023

Posted on

Access to prevention and treatment for all. Leave no one behind:

Organised by the Forum of International Respiratory Societies (FIRS) since 2016, World Lung Day is a time for everyone to take a look at what we can do individually and as a society, to work toward clean air and healthy lungs for all. Asthma is closely related to World Lung Day because it is one of the major lung health conditions that the day seeks to address.

Under-diagnosis of asthma

In 2019, asthma affected an estimated 262 million people worldwide1 and led to 455,000 deaths globally2. A study completed by Nolte et al. in 2006 involved 10,877 participants aged 14-44 years old, 11% (1,149) of whom had previously reported asthma symptoms. After further assessment provided by Global Initiative for Asthma (GINA) recommendations, 43% (493) of the 11% were diagnosed with asthma, of which a further 50% (246) had not been diagnosed before3.

When asthma remains undiagnosed or receives inadequate treatment, it can lead to stress, anxiety, or depression, as well as lung infections, hindered growth and delayed puberty in children. Additionally, it can escalate to critical asthma attacks that can be life-threatening4.

FeNO testing and asthma:

The use of FeNO testing, in conjunction with a comprehensive clinical history and additional examinations, contributes to more efficient asthma diagnosis and enhances patient care. Furthermore, it enables the monitoring of patients’ responses to asthma interventions.

FeNO testing can be completed within seconds and provides nearly instantaneous results, compared to traditional testing like spirometry with a bronchodilator test. Thereby ensuring a larger number of individuals receive appropriate treatment for their specific conditions, leading to reduced medication wastage5. In England, a two-year programme from 2021-2023 showed an estimated 58,000 people with newly diagnosed asthma received faster treatment, after more than 1,200 FeNO devices entered primary care6, highlighting the impact FeNO testing can have on asthma care.

Visit https://www.nobreathfeno.com to find out how you can support your patients with FeNO monitoring, with the NObreath® from Bedfont® Scientific Ltd.

References:

  1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, and Abdollahi M. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-1222. DOI: 10.1016/S0140-6736(20)30925-9.
  2. Asthma [Internet] World Health Organization. 2023. [Cited 24th August 2023]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  3. Nolte H, Nepper-Christensen S, and Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respiratory medicine. 2006;100(2):354-362. PMID: 16005621. DOI: 10.1016/j.rmed.2005.05.012
  4. The Global Asthma Report 2018 [Internet]. 2018. [Cited 25th August 2023]. Available from: http://globalasthmareport.org/2018/index.html
  5. Improving access to FeNO testing in primary care [Internet]. 2023. [Cited 25th August 2023]. Available from: https://www.ahsnnetwork.com/programmes/respiratory-disease/bettering-access-to-feno-testing-in-primary-care/
  6. New report shows impact of FeNO national programme on asthma care in England [Internet] Primary Care Respiratory Society. 2023. [Cited 24th August 2023]. Available from: https://www.pcrs-uk.org/news/new-report-shows-impact-feno-national-programme-asthma-care-england#:~:text=During%20the%20two%2Dyear%20programme,in%20primary%20care%20in%20England.

The National FeNO Programme: Accelerated Access Collaborative (AAC)

Posted on

The National FeNO Programme has recently released its Impact Report, promoting how their programme has improved access to fractional exhaled nitric oxide (FeNO) testing across the National Health Service (NHS) in England. The programme ran from April 2021 to March 2023.

The National FeNO Programme was part of a wider programme by the Accelerated Access Collaborative’s (AAC)’s Rapid Uptake Products Programme. The AAC brings together the NHS, patients, industry, government and more, with the goal of removing barriers to innovative and revolutionary new treatments and technology1. In England, the AAC has helped encourage the adoption of FeNO, with the help of the AHSN Network which delivered the programme as part of its commission from the NHS England Innovation Research and Life Sciences (IRLS) team1. The National FeNO Programme included two FeNO devices appraised by NICE, with NObreath®, manufactured by Bedfont® Scientific Ltd., being one of them.

What is FeNO?

FeNO is very minuscule particles of nitric oxide (NO), measured in parts per billion (ppb). NO is naturally produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath. The production of NO is often found to be higher in inflammatory conditions such as asthma and therefore FeNO monitoring can be used for the detection and management of such conditions.

Programme impact on FeNO device and testing

Over the duration of the programme, 1,244 new FeNO devices are now available in primary care. Notably, it is estimated that 53% of Primary Care Networks (PCNs) in England now have access to FeNO testing2, thanks to the National FeNO Programme. Yhe AAC and Office for Life Sciences (OLS), funded 33 national FeNO projects through their Pathway Transformation Fund (PTF), a total of £915,000 was given from the PTF, resulting in the implementation of 118 new FeNO devices.

Programme’s impact on education and funding for FeNO

The AHSN Network has supported training and development for FeNO testing, with two FeNO training modules developed for healthcare professionals. This has resulted in over 4,900 hours of training being delivered. A FeNO implementation toolkit was created as an aid to support the adoption of FeNO testing, and has been viewed over 13,500 times. After training modules were completed, a survey was carried out by 1,047 healthcare professionals enrolled on the FeNO training modules, 91% indicated the training will help in their role.

FeNO programme impact on asthma care for patients in England

During the course of the programme, the report estimates a potential 58,000 new asthmatics in England receiving an asthma diagnosis with the support of FeNO testing. In turn, helping to increase the accuracy and speed of the diagnosis of asthma, thus speeding up access to essential treatments for patients2.

What’s next?

The FeNO programme has now finished, but the incredibly important work around FeNO still continues. NICE, the Scottish Intercollegiate Guidelines Network (SIGN), and the British Thoracic Society (BTS) are currently developing joint asthma guidelines expected in 20243. In addition to this, the FeNO toolkit, training modules and resources developed during the AAC FeNO programme will remain accessible. Future opportunities still remain for improving asthma care in England, including the continuous sustainable growth of FeNO within primary and secondary care, and establishing a sustainable funding mechanism for FeNO testing across England.

With a handheld, portable, easy-to-use device, Bedfont® Scientific Ltd., is helping to break FeNO accessibility barriers. Previously FeNO breath analysis has been expensive, however, they have made it more cost-effective by having low-cost mouthpieces with a long shelf-life. The NObreath® includes a 5-year warranty on the device and sensor, and the service and maintenance options they offer have also been simplified. To find out how you can support your patients with FeNO monitoring, visit https://www.nobreathfeno.com.

Read the full National FeNO Programme Impact Report here:

https://wessexahsn.org.uk/img/projects/FeNO%20-%20national%20programme%20impact%20report%20-%20FINAL.pdf

References:

  1. NHS Accelerate Access Collaborative [Internet] NHS England. 2023. [Cited 5th July 2023]. Available from: https://www.england.nhs.uk/aac/
  2. National FeNO programme impact report [Internet]. Wessex Academic Health Science Network. 2023. [Cited 6th July 2023]. Available from: https://wessexahsn.org.uk/img/projects/FeNO%20-%20national%20programme%20impact%20report%20-%20FINAL.pdf
  3. FeNO programme impact report [Internet]. Wessex Academic Health Science Network. 2023. [Cited 10th July 2023]. Available from: https://wessexahsn.org.uk/projects/604/feno-programme-impact

Kent Company, Bedfont® Scientific Ltd, reveals New Well-being Garden, Nurturing Employee Wellness and Biodiversity

Posted on

Bedfont® opens a new wellness space for encouraging a carbon conscious approach and memorialising loved ones

Bedfont® proudly announces the successful transformation of unused space into a Wellbeing Garden. This innovative initiative not only underlines Bedfont’s commitment to its employees‘ wellness but also champions environmental conservation through biodiversity efforts. The garden, crafted using 90% reclaimed materials, serves as a touching memorial to lost loved ones.

Bedfont® encourages a healthy work-life balance and the Wellbeing Garden is a testament to this ethos, designed to provide employees with a serene and revitalising space to destress, recharge, and connect with nature. The garden’s carefully curated landscape also serves as a natural habitat for local flora and fauna, contributing to the preservation of local ecosystems, thanks to its variety of flowers and vegetables, and it even has a dedicated Bat box.

Managing Director, Jason Smith, remarks, “The Wellbeing Garden holds deep sentimental value as a memorial to lost loved ones, Niki and Pat. This garden was Niki’s dream and now it is a reality, underpinning the work she did promoting wellbeing for the Bedfont® Family. Pat, a beloved member of the Bedfont® Family and keen gardener, donated a lot of the greenery which now homes multiple ecosystems. Through this garden, not only does their memory live on, but it allows us to work towards our core value of being more Carbon Conscious, whilst providing a beautiful space for the Bedfont Family to promote wellbeing.”

Bedfont® extends its gratitude to the grant providers, Beyond Procurement, whose support made this visionary project a reality. The company remains steadfast in its commitment to nurturing a culture that prioritises employee welfare and environmental responsibility.

Bedfont® Boosts Cancer Research Fundraising Efforts with £200 Donation

Posted on

Bedfont® Scientific Ltd. helps fundraising reach £1000 for Cancer Research UK

Local Med-tech company, Bedfont® Scientific Ltd., is proudly donating £200 to support the noble fundraising efforts of its employees, the Bedfont® Family, who ran the Pretty Muddy 5K Obstacle Course on Saturday 1st July 2023, for Cancer Research UK. So far, the team have raised an inspiring £800 towards cancer research initiatives, meaning with Bedfont’s Donation the fundraising will reach an impressive £1000.

According to WHO, nearly every family globally is affected by cancer; 1 in 5 people are diagnosed with cancer during their lifetime, and the diagnosis affects the health and well-being of all those involved, including family members and caregivers1.

Jason Smith, Managing Director at Bedfont®, explained, “Our Bedfont® Family has very recently been affected by cancer and it has been a really difficult year for so many of us. I am inspired by the willpower of the Pretty Muddy runners, and wish to also contribute to a cause close to all of our hearts.”

The funds raised through this run will be directed to Cancer Research UK, to help groundbreaking cancer research and patient support. To donate, please visit: https://www.cancerresearchuk.org/get-involved/donate

References:

  1. Amplifying the lived experience of people affected by cancer [Internet]. World Health Organization; [cited 2023 Jul 3]. Available from: https://www.who.int/activities/amplifying-the-lived-experience-of-people-affected-by-cancer

Introducing CELLER8®: Revolutionising Wellness with PEMF Technology

Posted on

Med-tech manufacturer, Bedfont® Scientific Ltd., launches new CELLER8® PEMF device with exclusive distributor, NewMed Ltd. at the Health Optimisation Summit 2023

Bedfont®, a leading innovator in medical devices with over 40 years of manufacturing experience, proudly announces the launch of a new PEMF (Pulsed Electromagnetic Field) device, CELLER8®. With NewMed Ltd. as the global exclusive distributor, the CELLER8® was introduced at the Health Optimisation Summit 2023.

CELLER8® harnesses the power of Pulsed Electromagnetic Field therapy, using the earth’s natural magnetic waves to concentrate and send electromagnetic pulses to specific areas of the body. The underlying principle of PEMF therapy is that it aims to restore balance by supporting healthy cellular function, promoting circulatory wellness, and supporting overall health and wellness.

Jason Smith, Managing Director at Bedfont®, comments, “With over 40 years of manufacturing experience from Bedfont®, and NewMed’s PEMF knowledge, we’ve combined our joint expertise and passion for driving innovation to develop a PEMF device with the user in mind. This summit is the ideal location to launch CELLER8® as the summit focuses on everything in the general health, wellbeing, nutrition, biohacking and fitness worlds.”

Andy Smith, Managing Director at NewMed, adds, “Having benefited from PEMF therapy myself, I founded NewMed to help others learn about and experience this life changing technology. I’m proud to say we’re the one-stop-shop for PEMF devices, and we’re excited to be launching the CELLER8® – it’s compact, sleek, and powerful – perfect for individuals seeking natural, non-invasive, solutions to enhance their overall health and well-being.”

The CELLER8® was launched at the Health Optimisation Summit, which took place 17th – 18th June, at the Business Design Centre, London. Visit http://www.celler8.com for more information.

World No Tobacco Day – 31st May 2023

Posted on

World No Tobacco Day is an annual awareness day that informs the public about the dangers of using tobacco1. This year’s campaign, ‘Grow food, not tobacco’, encourages the government to end tobacco growing subsidies and use the savings to support farmers to switch to more sustainable crops that improve food security and nutrition1.

Worldwide, approximately 5.89 million metric tonnes of tobacco is produced every year2, contributing to an estimated 1.1 billion active tobacco smokers worldwide3. Bedfont‘s Smokerlyzer® range has been an integral part of the post-smoking process for over 35 years. By providing users with instant Carbon Monoxide (CO) readings and a motivational traffic light system to guide them towards their quit goals, we have helped countless individuals towards their stop smoking goals and improve their overall health and well-being.

It is reported that globally in 2020, tobacco use consisted within the everyday lives of 36.7% of men and 7.8% of the world’s women4. Within the UK, data recorded that in 2020 the proportion of current smokers was 14%, fast-forward to 2021 and that statistic has seen a significant decrease, equating to 13.3%, which corresponds to an estimated 6.6 million people in the UK who are classified as current smokers5.

A study regarding the use of a CO device to quit smoking gathered 10 smokers, who of which received a CO device and were asked to use it regularly throughout the day for 6 weeks with the aim of maintaining their CO reading below 10ppm. At the 6-week follow-up, all participant’s CO concentrations were below their baseline value; two were below 10ppm. The average daily cigarette consumption reduced from 14.1 at baseline to 9.8 during the 2 weeks of daily CO monitoring, and then 9.5 at the 6-week follow-up. Concluding that the use of the CO device was generally found to be acceptable and to increase motivation to stop smoking completely, as five smokers out of the ten attempted to quit smoking6.

The Smokerlyzer® range by Bedfont® consists of 4 handheld breath analysis devices, Micro+™, piCObaby™, piCO™, and iCOquit® – each of which tests the level of CO on a smoker’s breath, which can help them understand the harmful effects that smoking has on their body. When a person smokes, they inhale carbon monoxide, which is a poisonous gas that can lead to serious health problems. The on-screen instant results for each device, coupled with the interpretation guide provided, help patients quickly identify which traffic light system bracket they fall into. This enables them to take proactive steps towards quitting smoking and improving their health.

Visit https://www.bedfont.com/smokerlyzer to learn more about how you can aid patients to stop smoking, one breath at a time, with Bedfont® Scientific Ltd’s Smokerlyzer® range.

References:

  1. World No Tobacco Day [Internet]. World Health Organization. World Health Organization; [cited 2023Apr28]. Available from: https://www.who.int/campaigns/world-no-tobacco-day
  2. Shahbandeh M. Global tobacco production 2021 [Internet]. 2023 [cited 2023 May 15]. Available from: https://www.statista.com/statistics/261189/global-tobacco-production-since-1980/
  3. The global burden of tobacco – the Lancet [Internet]. [cited 2023 May 15]. Available from: https://www.thelancet.com/infographics-do/tobacco
  4. Tobacco [Internet]. World Health Organisation. 2022. [Cited 2nd May 2023]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/tobacco
  5. Adult smoking habits in the UK: 2021. [Internet]. Office for National Statistics. 2022. [Cited 2nd May 2023]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/bulletins/smokingprevalenceintheukandtheimpactofdatacollectionchanges/2020
  6. Beard E, and West R. Pilot study of the use of personal carbon monoxide monitoring to achieve radical smoking reduction. Journal of Smoking Cessation. 2012;7(1):12-17. DOI: 10.1017/jsc.2012.1.

World Asthma Day – 2nd May 2023

Posted on

Organized by the Global Initiative for Asthma (GINA), World Asthma Day is an annual awareness day aimed at raising awareness of asthma and improving healthcare, with this year’s theme focusing on ‘Asthma care for All’1. Thanks to over 15 years of experience in FeNO monitoring, Bedfont® Scientific Ltd has developed a FeNO breath analysis device that can aid in the diagnosis and management of asthma. Bedfont® is working to increase access to FeNO monitoring worldwide through its dedicated network of distributors and Key Opinion Leaders.

Did you know that worldwide asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths?2 The central process within asthma and many other lung diseases is airway inflammation, and being able to detect airway inflammation levels and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.

When airways are inflamed Nitric Oxide (NO) is naturally produced by your body to help combat inflammation. This production of NO is often found to be higher in inflammatory conditions such as asthma, and an innovative way of detecting and managing such conditions is done through FeNO monitoring. Two funded projects in the UK have presented data from a staff survey in primary care that shows that 83% of survey respondents have felt that FeNO testing has improved confidence levels when diagnosing asthma, and 90% believe that access to FeNO testing has supported the diagnosis of asthma with patients3.

Fractional exhaled Nitric Oxide (FeNO) is a measure of the concentration of NO gas particles in exhaled breath, expressed in parts per billion (ppb). The NObreath® FeNO device by Bedfont® Scientific Ltd. is easy to use with its simple exhale-only technique and on-screen visual motivation. With over 10 years of clinical use featuring in many studies worldwide, the NObreath® FeNO device aids in the diagnosis & management of asthma for both adult and child patients, giving you the ability to also store up to 25 results in up to 50 patient profiles with full graph results.

With a handheld, portable, easy-to-use device, Bedfont® is helping to break FeNO accessibility barriers. Previously FeNO breath analysis has been expensive, however, we have made it more cost-effective by having low-cost mouthpieces with a long shelf-life. The NObreath® includes a 5-year warranty on the device and sensor, and we have also simplified the service and maintenance options. To find out how you can support your patients with FeNO monitoring to improve ‘Asthma care for All’ this World Asthma Day, visit https://www.nobreathfeno.com.

References:

1. Rurey K. 2023 World Asthma Day – Global Initiative for Asthma [Internet]. GINA. 2023 [cited 2023Apr4]. Available from: https://ginasthma.org/2023-world-asthma-day/

2. Asthma [Internet]. World Health Organization. World Health Organization; [cited 2023Apr17]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma

3. Feno testing in Primary Care [Internet]. West of England Academic Health Science Network. 2023 [cited 2023Apr17]. Available from: https://www.weahsn.net/our-work/case-study/feno-testing-in-primary-care/

Back to top